Skip to main content
. 2021 Feb 3;19:51. doi: 10.1186/s12967-021-02722-8

Fig. 5.

Fig. 5

CtDNA and CA125/HE4 detection in disease-free and relapsed patients. a CtDNA tracking profile of 6 patients who are currently disease free at baseline and after standard treatment of high-risk endometrial cancer. Mutations were undetectable in the post-surgical follow-up periods in 5 of 6 patients. The remaining patient (EM003, red), with stage IIIC2 serous carcinoma showed ctDNA at 8 months after surgery, but did not have clinical relapse at the time of reporting (26 months after surgery). b CtDNA tracking profiles from three patients who experienced relapse at baseline and after standard treatment. CtDNA was detected in all cases at the time of or before relapse. c CA125 and HE4 tracking profiles from three patients who experienced relapse at baseline and after standard treatment. Orange dash lines denote the upper normal limit of CA125 in our hospital (35U/mL), blue dash lines denote different upper normal limits of HE4 with different age ranges (EM001, 50–59 years old, 70 pmol/L; EM002, above 70 years old, 140 pmol/L; EM005, 60–69 years old, 80 pmol/L). d Table showing ctDNA, CA125, HE4, imaging, and tumor relapse. CtDNA had higher sensitivity and specificity than CA125 and HE4 and had comparable performance with imaging in tumor relapse detection